The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Efficacy of subsequent therapies for CLL patients treated in the MURANO trial
John Seymour, MBBS, FRACP, PhD, Peter MacCallum Cancer Centre, East Melbourne, Australia, discusses outcomes of subsequent therapies in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) treated with venetoclax plus rituximab compared to bendamustine plus rituximab in the MURANO trial (NCT02005471). There was a significant benefit in progression-free survival (PFS) for patients treated in the venetoclax arm, and follow-up therapy with both venetoclax-based regimens and BTK inhibitors was feasible. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: AstraZeneca, AbbVie, Beigene, BMS, Gilead, Hoffmann-La Roche, Janssen; Membership on an entity’s Board of Directors or advisory committees: AstraZeneca, AbbVie, Beigene, Genor Bio, BMS, Gilead, Hoffmann-La Roche, Janssen; Research Funding: AbbVie, F. Hoffmann-La Roche Ltd; Speakers Bureau: AbbVie, Beigene, Hoffmann-La Roche; Consultancy: TG Therapeutics, BMS, Hoffmann-La Roche.
